About this trial

The main purpose of this study is to explore the value of multimodal imaging information and models in predicting the prognosis of EGFR-positive non-small cell lung cancer patients undergoing targeted therapy, providing a basis for selecting suitable populations for precise tumor treatment and corresponding therapy. We retrospectively analyzed patient case data, extracted preoperative CT images, H\&E-stained whole-slide digital pathology images, and pre- or postoperative genetic testing reports to extract radiomic features of tumor and peritumoral regions. These features were combined with multidimensional pathological features and gene expression distribution characteristics to construct a multimodal radiopathogenomic model, offering more precise prognostic evaluation for lung cancer patients receiving targeted therapy.

Eligibility criteria

Qualifiers

Age 18-80 years, undergoing radical surgery for lung cancer (R0 resection);

Postoperative pathological stage IB-IIIA, pathology confirmed as adenocarcinoma;

EGFR gene testing positive, EGFR 19del/L858R mutation;

Receiving postoperative EGFR-TKI targeted adjuvant therapy;

Disqualifiers

Patients negative for EGFR;

Incomplete surgical resection (R1, R2);

Did not receive EGFR-TKI targeted therapy after surgery;

Recurrent or advanced stage patients;

Trial design

Treatments tested in this trial

  • Comprehensive analysis through laboratory tests, imaging techniques, and clinical data

Treatment groups

No treatment groups listed

Locations

1
Wuhan Union Hospital430022, WuhanHubei, China

Sponsors and collaborators

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Lead sponsor